AstraZeneca’s (AZN) Sector perform Rating Reiterated at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “sector perform” rating reiterated by Deutsche Bank Aktiengesellschaft in a report released on Tuesday,Digital Look reports. They currently have a £115 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential downside of 1.99% from the stock’s previous close.

Several other brokerages also recently weighed in on AZN. Berenberg Bank reaffirmed a “buy” rating and set a £160 target price on shares of AstraZeneca in a research note on Tuesday, July 28th. Citigroup lifted their price target on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Monday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of £152.17.

AstraZeneca Stock Performance

Shares of AZN stock opened at £117.34 on Tuesday. The company has a market capitalization of £181.98 billion, a P/E ratio of 17.67, a P/E/G ratio of 0.86 and a beta of 0.23. The business’s 50 day moving average is £133.56 and its two-hundred day moving average is £140.06. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. AstraZeneca has a 12-month low of £107.84 and a 12-month high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.